US pharma giant Pfizer’s (NYSE: PFE) Abrysvo has won US approval for use in pregnant women to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through six months of age.
The approval adds to the battle between Pfizer and GSK (LSE: GSK) in this field, with the UK drugmaker having gained US approval of a RSV vaccine with its Arexvy product in May.
Importantly, Pfizer is the only company with an RSV vaccine to help protect older adults, as well as help protect infants through maternal immunization, having initially been granted US Food and Drug Administration (FDA) approval for Abrysvo for the prevention of LRTD caused by RSV in patients of at least 60 years in May of this year, shortly after the GSK nod.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze